ImaRx Therapeutics
Founded Year
1999Stage
Unattributed VC - IV | AliveTotal Raised
$31.37MLast Raised
$15M | 17 yrs agoAbout ImaRx Therapeutics
We are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. In addition to the brain and the lungs, blood clots can block blood flow and cause damage to other tissues in the body such as the heart, in case of coronary arterial disease, and the legs and other extremities, in case of peripheral vascular disease. We believe our development and research stage products may address significant unmet medical needs not only for stroke but also for clot-induced damage in tissues other than the brain.
Missing: ImaRx Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ImaRx Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
ImaRx Therapeutics Frequently Asked Questions (FAQ)
When was ImaRx Therapeutics founded?
ImaRx Therapeutics was founded in 1999.
Where is ImaRx Therapeutics's headquarters?
ImaRx Therapeutics's headquarters is located at 12277 134th NE, Redmond.
What is ImaRx Therapeutics's latest funding round?
ImaRx Therapeutics's latest funding round is Unattributed VC - IV.
How much did ImaRx Therapeutics raise?
ImaRx Therapeutics raised a total of $31.37M.
Who are the investors of ImaRx Therapeutics?
Investors of ImaRx Therapeutics include Solstice Capital, Edson Moore Healthcare Ventures and Coronado Venture Fund.
Who are ImaRx Therapeutics's competitors?
Competitors of ImaRx Therapeutics include Viracta, Juventas Therapeutics, Arteriocyte, Proteon Therapeutics, Akebia Therapeutics and 14 more.
Compare ImaRx Therapeutics to Competitors
EndGenitor scientists are also engaged in exciting research to novel methods for stimulating and promoting blood vessel formation and growth.
CSF Therapeutics is developing a cerebral blood flow device to prevent neurological debilitation and death, affecting more than 10 million individuals in the US alone, and includes indications such as stroke and Alzheimer's disease. Based on the research at The Cleveland Clinic, CSF Therapeutics' device is designed to increase cerebral blood flow indefinitely without affecting vascular or systemic function.
Procyon Pharmecuticals, Inc. is an veterinary pharmecutical research and development company with a robust, theraputically diverse pipeline of products being developed to meet the needs of veterinarians and pet owners.
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.
Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.